Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.

Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.

View in: PubMed

subject areas

Adult
Antibodies, Monoclonal, Humanized
Biological Therapy
Biomarkers
Chicago
Colitis, Ulcerative
C-Reactive Protein
Crohn Disease
Drug Administration Schedule
Female
Humans
Logistic Models
Male
Middle Aged
Multivariate Analysis
Prospective Studies
Remission Induction
Tumor Necrosis Factor-alpha
Wound Healing

authors with profiles

Christopher Weber
Dejan Micic
David T. Rubin
Russell D. Cohen